OPN-6602 is Currently in a Phase 1 Clinical Trial for Relapsed/Refractory Multiple Myeloma SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–February 12, 2025– Opna Bio, a clinical-stage biopharmaceutical ...
SAN DIEGO--(BUSINESS WIRE)--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced interim data from its lead clinical ...
In the modified intent-to-treat population, the rate of post-operative complications at 30 days was 37% in the RAPN arm and 46% in the OPN arm. Patients with intermediate- or high-complexity renal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results